Metastatic melanoma treatment currently relies on immune checkpoint inhibitors (ICIs) and targeted therapies, with BRAF and MEK inhibitors used in patients with BRAF V600E mutations [3,4]. The gene discussed is BRAF; the disease is melanoma.